The__O body__O of__O research__O published__O by__O the__O Cosstick__B-ORG group__O from__O the__O 1990's__O through__O to__O the__O present,__O has__O described__O a__O wealth__O of__O information__O relating__O to__O the__O chemistry__O and__O biochemistry__O of__O the__O 3'-sp__O linkages.__O
Oligonucleotides__O containing__O this__O 3'-sp__O linkage__O are__O an__O essential__O component__O in__O a__O DNA__B-MISC sequencing__O method__O known__O as__O SOLiD&#8482;__O (Sequencing__O by__O Oligonucleotide__B-ORG Ligation__I-ORG and__O Detection).__B-LOC
SOLiD__O sequencing__O was__O launched__O by__O Applied__B-ORG Biosystems__I-ORG Inc__I-ORG (ABI,__O now__O incorporated__O into__O Life__B-ORG Technologies__I-ORG as__O of__O 2008)__O in__O 2007__O and__O the__O SOLiD__B-ORG sequencing__O instruments__O became__O commercially__O available__O in__O 2008.6,7__O The__B-MISC SOLiD__I-MISC method__O is__O based__O on__O sequencing__O by__O ligation__O and__O uses__O universal__O sequencing__O primers__O (essentially__O short__O oligonucleotides__O containing__O the__O 3-sp__O linkage)__O to__O interrogate__O the__O DNA__B-ORG template__O to__O be__O sequenced.__O
The__O sequence__O is__O read__O through__O rounds__O of__O hybridisation,__O ligation,__O detection__O and__O cleavage.__O
The__O cleavage__O step__O removes__O the__O fluorescent__O label__O (required__O for__O the__O detection__O step)__O from__O the__O 5'-end__O of__O the__O oligonucleotide__O and__O resets__O the__O system__O for__O the__O next__O round__O of__O hybridisation__O and__O ligation,__O so__O that__O the__O next__O nucleotide__O can__O be__O sequenced.__O
The__O specific__O cleavage__O step__O of__O the__O 3'-sp__O linkage,__O which__O is__O conducted__O under__O mild__O conditions__O compatible__O with__O the__O requirements__O of__O the__O SOLiD__B-MISC method__O using__O aqueous__O silver__O ions__O as__O demonstrated__O by__O Cosstick,1__O is__O crucial:__O at__O the__O time__O when__O the__O method__O was__O developed,__O no__O other__O of__O DNA__B-ORG modification__O was__O known__O to__O work__O in__O SOLiD__O sequencing.__O
Details__O of__O the__O sequencing__O method__O and__O the__O role__O of__O the__O 3'-sp__O linkage__O are__O clearly__O evident__O from__O the__O patents__O of__O McKernan8__O and__O from__O a__O review__O article__O on__O sulfur__O analogues__O of__O nucleic__O acids__O by__O Zon.9__B-ORG Cosstick's__I-ORG chemistry__O was__O thus__O decisive__O in__O enabling__O implementation__O of__O SOLiD__B-ORG sequencing.__O
It__O was__O subsequently__O shown__O that__O SOLiD__B-ORG sequencing__O can__O also__O be__O performed__O in__O what__O is__O known__O as__O "the__O reverse__O direction"__O using__O the__O isomeric__O 5'-sp__O linkages,8,9__O but__O in__O this__O case__O an__O additional__O step__O is__O necessary__O to__O remove__O the__O 3'-phosphate__O prior__O to__O ligation.__O
In__O 2006,__O ABI__B-ORG were__O working__O on__O the__O development__O of__O their__O SOLiD__B-ORG sequencing__O method__O and__O needed__O to__O produce__O oligonucleotides__O containing__O the__O 3'-sp__O linkages__O on__O a__O large-scale,__O as__O these__O were__O essential__O reagents__O for__O the__O SOLiD__B-ORG instruments.__O
Their__O synthetic__O approach__O to__O the__O large-scale__O synthesis__O of__O these__O oligonucleotides__O was__O principally__O based__O on__O scaling-up__O the__O synthetic__O procedures__O published__O by__O Cosstick__B-ORG in__O 2004.2__O On__O invitation__O from__O Dr__B-ORG Gerry__I-ORG Zon__I-ORG (then__I-ORG director__O of__O sequencing__O chemistry),__O Cosstick__O visited__O the__O ABI__B-ORG chemistry__O labs__O (Foster__B-ORG City,__I-ORG CA,__I-ORG USA)__I-ORG in__O October__O 2006__O for__O detailed__O discussions__O relating__O to__O some__O of__O the__O difficulties__O the__O chemistry__O sequencing__O group__O had__O encountered__O with__O the__O synthesis__O of__O 3'-sp__O modified__O oligonucleotides.__O
At__O that__O time__O there__O was__O considerable__O urgency__O to__O establish__O an__O efficient__O method__O for__O the__O production__O of__O the__O 3'-sp__O modified__O oligonucleotides__O in__O order__O to__O meet__O the__O demand__O for__O these__O reagents__O when__O the__O instruments__O became__O commercially__O available.__O
In__O terms__O of__O their__O performance,__O the__O latest__O SOLiD__B-ORG instruments__O (5500__O series__O genetic__O analysers)__O deliver__O greater__O than__O 90__O giga__O base-pairs__O of__O sequence__O information__O in__O one__O day__O and__O a__O 7__O day__O run__O can__O complete__O the__O sequence__O of__O the__O human__O genome.__O
The__O two-base__O encoding,__O which__O is__O unique__O to__O the__O SOLiD__B-ORG method,__O provides__O exceptional__O sequencing__O accuracy__O at__O &gt;99.94%,__B-LOC (for__O further__O information__O see:__O http://tools.lifetechnologies.com/content/sfs/brochures/cms_057511.pdf),10__O as__O each__O nucleotide__O in__O the__O sequence__O is__O essentially__O read__O twice.__O
The__O SOLiD__B-MISC technology__O is__O one__O of__O several__O so-called__O second/next-generation__O sequencing__O systems__O (together__O with__O instruments__O from__O Illumina,__B-PER Roche__I-PER and__O to__O a__O lesser__O extent__O Helicos)__O which__O were__O available__O as__O of__O 2008.__O
Each__O of__O these__O sequencing__O systems__O seems__O to__O have__O its__O own__O advantages__O and__O limitations,__O although__O in__O 2011__O the__O SOLiD__B-ORG system__O was__O reported__O to__O have__O the__O lowest__O reagent__O cost__O needed__O to__O reassemble__O a__O human__O genome11__O and__O came__O top__O in__O the__O J.P.__O Morgan__B-ORG Next__I-ORG Generation__I-ORG Sequencing__I-ORG Survey12__I-ORG (published__O in__O 2010)__O for__O accuracy.__O
Accuracy__O was__O also__O shown__O to__O be__O the__O most__O important__O attribute__O when__O choosing__O a__O DNA__B-ORG sequencing__O system.12__O The__O estimated__O sales__O value__O of__O SOLiD__B-ORG sequencing__O systems__O to__O Life__B-ORG Technolgies__I-ORG is__O also__O presented__O in__O the__O J.P.__O Morgan__B-ORG survey12__O and__O rose__O from__O zero__O in__O 2007__O to__O $68__O million__O in__O 2008,__O $100million__O in__O 2009__O and__O predicted__O sales__O of__O $136.9__O million__O in__O 2010,__O $178__O million__O in__O 2011__O and__O $222.5__O million__O in__O 2012__O (figures__O based__O on__O J.P.__B-ORG Morgan__I-ORG estimates__O and__O company__O reports12).__O
In__O 2010,__O only__O two__O years__O after__O becoming__O commercially__O available,__O the__O SOLiD__B-ORG instrument__O was__O estimated__O to__O have__O about__O 20%__O market__O share__O for__O second/next-generation__O sequencing__O and__O was__O predicted__O to__O rise__O to__O 22.6%__O (second__O largest__O market__O share__O after__O Illumina)__B-ORG by__O 2012.12__O New__O jobs__O created__O by__O commercialization__O of__O SOLiD__B-ORG sequencing__O include__O USA-based__B-MISC manufacturing__O of__O consumable__O reagents,__O world-wide__O hiring__O of__O technical__O specialists__O to__O support__O customers,__O and__O (especially)__O world-wide__O sample__O preparation,__O sequencing__O and__O bioinformatics__O analysis__O at__O service-provider__O facilities.__O
The__O benefit__O of__O the__O SOLiD__B-MISC sequencing__O system__O goes__O beyond__O that__O of__O generating__O economic__O impact,__O as__O the__O technology__O is__O now__O enabling__O patients__O to__O benefit__O from__O personalised__O medicine__O derived__O from__O DNA__B-ORG sequence__O information.__O
For__O example,__O whole__O genome__O sequencing__O (conducted__O with__O the__O SOLiD__B-ORG 4__O instrument)__O of__O twins__O with__O dopamine-responsive__O dystonia,__O a__O clinically__O complex__O neurological__O movement__O disorder,__O that__O is__O normally__O treated__O with__O L-dopa,__B-MISC identified__O unexpected__O mutations__O in__O the__O gene__O encoding__O sepiapterin__O reductase.__O
This__O enzyme__O is__O responsible__O for__O the__O synthesis__O of__O co-factors__O required__O for__O the__O synthesis__O of__O dopamine__O and__O seratonin.__O
Supplement__O of__O the__O L-dopa__B-LOC therapy__O with__O a__O serotonin__O precursor__O resulted__O in__O considerable__O clinical__O improvements__O in__O both__O twins.13__O The__O exceptional__O accuracy__O of__O the__O 2-base__O encoding__O means__O that__O SOLiD__B-ORG sequencing__O is__O ideally__O suited__O to__O cancer__O research/diagnosis,__O because__O tumors__O contain__O mixed__O sub-populations__O with__O different__O mutations.__O
Deep-sequencing__O on__O the__O SOLiD__B-ORG platform__O has__O revealed__O differential__O expression__O of__O microRNAs__O in__O favourable__O versus__O unfavourable__O neuroblastoma__O (the__O most__O common__O extracranial__O solid__O tumor__O of__O childhood)__O and__O provides__O a__O reliable__O method__O to__O assess__O the__O aggressiveness__O and__O hence__O prognosis__O of__O the__O tumor.14__O Whilst__O just__O two__O specific__O examples__O are__O presented__O here,__O they__O indicate__O the__O tremendous__O scope__O of__O the__O SOLiD__B-ORG sequencing__O technique__O to__O aid__O diagnosis__O and__O treatment__O of__O a__O wide__O range__O of__O diseases.__O
There__O is__O a__O list__O of__O over__O 100__O publications__O resulting__O from__O SOLiD__B-ORG sequencing__O at__O the__O Life__B-ORG Technologies__I-ORG website__O which__O cover__O applications__O on:__O sequencing__O accuracy,__O bioinformatics,__O de__O novo__O sequencing,__O targeted__O resequencing__O and__O transcriptome__O analysis__O (further__O details__O available__O at:__O http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Next-Generation-Sequencing/Publications-Literature.html__O )10__O The__O wealth__O of__O research__O that__O was__O conducted__O by__O the__O Cosstick__B-MISC group__O on__O DNA__B-ORG containing__O the__O 3'-S-phosphorothiolate__B-ORG linkage__O has__O been__O absolutely__O crucial__O to__O the__O development__O of__O SOLiD__B-ORG sequencing.__O
The__O contribution__O that__O the__O work__O in__O Liverpool__B-ORG made__O to__O the__O SOLiD__B-ORG programme__O has__O been__O corroborated__O by__O Dr__B-ORG Gerry__I-ORG Zon15__I-ORG (letter__O available)__O who__O was__O directing__O the__O ABI__B-ORG chemistry__O sequencing__O group__O in__O Foster__B-LOC City__I-LOC (USA)__O at__O the__O time__O SOLiD__B-ORG sequencing__O was__O being__O developed.__O
To__O quote__O from__O Dr__B-ORG Zon's__I-ORG letter,__O "the__O scale-up__O of__O the__O synthesis__O of__O the__O phosphorothiolate-containing__O DNA__B-ORG reagents__O had__O to__O be__O done__O in__O a__O very__O short__O period__O of__O time,__O because__O of__O competing__O sequencing__O techniques__O which__O were__O due__O to__O come__O on__O the__O market.__O
It__O was__O an__O enormous__O benefit__O therefore__O to__O be__O able__O to__O use__O and__O adapt__O your__O published__O procedures,__O particularly__O the__O automated__O synthesis__O of__O the__O phosphorothiolate__O oligomers__O you__O published__O in__O 2004"__O (reference__O 2).__O
To__O quote__O further,__O "from__O the__O work__O you__O had__O published__O (reference__O 3__O is__O quoted__O in__O the__O letter,__O it__O was__O apparent__O that)__O the__O phosphorothiolate__O reagents__O would__O be__O fully__O compatible__O with__O all__O aspects__O of__O the__O sequencing__O technique__O (and)__O gave__O ABI__B-ORG confidence__O to__O commit__O to__O the__O technique".__O
